Endogenous copper-binding tripeptide
GHK-Cu
Glycyl-L-Histidyl-L-Lysine copper(II) tripeptide complex — an endogenous copper-binding peptide first isolated from human plasma
Overview
GHK-Cu is unusual among the peptides on Healthy Mango in one specific respect: it is not a synthetic research compound at all. It is a naturally occurring tripeptide — glycyl-L-histidyl-L-lysine — bound to copper(II) as its physiologically active form. Loren Pickart isolated the sequence from human plasma in 1973 and immediately noted its copper-binding behaviour. That fifty-year continuous research history is one editorial anchor for how the compound should be read.
The mechanistic story turns out to be less about the peptide than about the metal it carries. Copper is an essential micronutrient — a cofactor for lysyl oxidase (extracellular matrix cross-linking), superoxide dismutase (antioxidant defense), cytochrome c oxidase (mitochondrial energy production), and dopamine β-hydroxylase (neurotransmitter synthesis). Cells need copper delivered to them, but free copper is cytotoxic. Endogenous copper-transport proteins (ceruloplasmin, ATP7A, ATP7B, the copper chaperones) exist precisely because copper delivery is a solved biological problem. GHK-Cu is one participant in that transport system: the tripeptide chelates copper stably at physiological pH, delivers it into cells, and releases it to intracellular targets.
The consequence of this mechanism is what makes GHK-Cu editorially distinctive. Because copper acts as cofactor for so many enzymes across so many pathways, delivering copper to cells produces downstream gene-expression changes in an enormous number of genes. Pickart and Margolina published genome-wide microarray studies characterising this footprint: at physiological GHK-Cu concentrations, approximately 4200 human genes are significantly modulated, including genes involved in DNA repair, extracellular matrix synthesis, antioxidant defense, angiogenesis, and inflammatory response. This is not a compound with 'a mechanism' in the singular sense. It is a compound with a mechanism (copper delivery) whose downstream consequences are inherently broad.
The clinical evidence structure follows from this. GHK-Cu has been used as a cosmetic ingredient for decades under the INCI name 'Copper Tripeptide-1,' with an established industry safety and efficacy record. The 2022 systematic review by Zhang et al. in Journal of Cosmetic Dermatology consolidated the topical clinical evidence for wound healing, dermal regeneration, and anti-aging applications. That is the strongest human evidence base for any peptide in Healthy Mango's tissue-repair category. Injectable and systemic GHK-Cu use has less controlled human evidence — but the topical/cosmetic base is genuinely more substantial than what supports BPC-157 or TB-500 in their popular use cases.
Quick Facts & Evidence
- Category
- Endogenous copper-binding tripeptide
- Research area
- Copper peptide
- Most studied for
- Skin wound healing and dermal regeneration (topical, extensive)
- Hair growth and hair-follicle biology (topical)
- Anti-oxidant and anti-inflammatory dermatology applications
- Systemic tissue repair (injectable, more limited controlled evidence)
- Clinical status
- Established clinical use
- Human evidence
- Moderate Human Evidence
- Regulatory status
- Not approved by FDA, EMA or MHRA
Moderate Human Evidence
Supported by human trials, but of limited size, duration, or replication. May be approved for related but not identical indications.
Research Protocols
Research Protocol Snapshot
Preparation covered on this page
Freeze-dried injectable research format
This page covers the injectable RUO lyophilized GHK-Cu vial reconstituted with bacteriostatic water for subcutaneous research use, following the standard Healthy Mango preparation convention. Topical cosmetic formulations are a separate presentation with their own storage instructions.
GHK-Cu research values at a glance.
| Item | Example value |
|---|---|
| Vial size | 50 mg |
| Liquid used to mix | Bacteriostatic water |
| Amount of liquid added | 5.0 mL |
| Final concentration | 10 mg/mL |
| How it's given | Subcutaneous injection |
| Research dose | 1–2 mg |
| Frequency | 5 times per week |
| Duration | Typically continuous; no fixed cycle established |
Reported Dosing
The practitioner-reference research protocol for GHK-Cu is 1–2 mg per subcutaneous injection, five times per week, used continuously with no fixed cycle. It is educational reference, not a recommendation.
The Reported Protocol
| Dose | Frequency | Duration | Notes |
|---|---|---|---|
| 1–2 mg | 5 times per week, subcutaneous | Typically continuous; no fixed cycle established | 0.10–0.20 mL at 10 mg/mL |
Why protocols vary
GHK-Cu acts as a broad gene-expression regulator; its research effects build cumulatively at the transcription-factor level rather than from a single-dose pulse. The 5x/week workweek cadence gives regular exposure without a specific pulsatility requirement.
Topical cosmetic use of GHK-Cu is a separate presentation with a different pharmacokinetic profile. The injectable protocol reaches systemic tissue-repair targets that a topical application does not.
Preparing the Solution
Turning the freeze-dried powder into a measurable liquid.
Documented preparation
The documented research protocol is based on this preparation concentration.
Freeze-dried powder: 50 mg vial
Diluent: 5.0 mL bacteriostatic water
Final concentration: 10 mg/mL
Vial and volume from the practitioner reference; concentration calculated · Research-practitioner guide
Your vial
Matching preparation
Bacteriostatic water
5mL
Resulting concentration
10 mg/mL
Equivalent volume
The reported research amount of 1–2 mg is contained within
0.1–0.2mL
of the prepared solution now in your vial.
Show calculation
- Documented concentration
- 50 mg ÷ 5 mL = 10 mg/mL
- Bacteriostatic water to match the documented concentration
- 50 mg ÷ 10 mg/mL = 5 mL
- Equivalent volume at this concentration
- 1–2 mg ÷ 10 mg/mL = 0.1–0.2 mL
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.Sources for these values
- Documented in the practitioner referenceResearch-practitioner guide
This example explains how concentration and volume are calculated for the standard RUO preparation. It is not a preparation guide.
How It's Given
Method used for this format
Subcutaneous injection, 5 times per week
Documented in the practitioner reference · Research-practitioner guide
Why this method
GHK-Cu is a copper-bound tripeptide; the subcutaneous route delivers the complex into circulation without the gastrointestinal degradation that would disrupt the copper binding.
Systemic subcutaneous dosing is used because the mechanism relies on tissue-wide gene expression, not on a localised depot.
Injection sites reported
- Abdomen (rotate sites)
- Front of the thigh
- Back of the upper arm
- Avoid scarred, bruised, inflamed, or infected skin
Storage
Before mixing
- Refrigerate 2–8 °C
- Protect from light
- Do not freeze
General RUO practice · Research-practitioner guide
After mixing
- Refrigerate 2–8 °C
- Use within 7–10 days
- Do not freeze
- Discard if cloudy or discoloured
General RUO practice · Research-practitioner guide
Handling
- Direct diluent slowly down the vial wall
- Gently swirl until dissolved — do not shake
- New sterile needle each draw
- Do not share vials
General RUO practice · Research-practitioner guide
Storage guidance summarises standard RUO peptide handling for the injectable presentation. Topical cosmetic formulations follow their own product-specific storage instructions.
Common Cycle
The practitioner reference frames injectable GHK-Cu as continuous 5x/week dosing without a fixed on/off cycle.
- Cycle Length
- Continuous 5x/week dosing
- Break Before the Next Cycle
- No fixed cycle established
- What the Research Shows
- Topical dermatology trials of copper-peptide formulations have run 4–12 weeks; injectable use has no equivalent published trial timeline
Documented in the practitioner reference · Research-practitioner guide
Injectable use is off-label; the peer-reviewed evidence base (Pickart 1973 onward) covers topical, cosmetic, and mechanistic contexts more comprehensively than injectable systemic dosing.
Compound Overview
Current areas of research
The following effects are supported by preclinical and clinical evidence appropriate to each use case. Topical cosmetic uses have the strongest human evidence base; systemic injectable uses have more limited controlled data.
- Topical skin wound healing and dermal regeneration (Zhang 2022 systematic review; extensive cosmetic-industry evidence)
- Anti-aging cosmetic effects — collagen and elastin synthesis via copper cofactor delivery (Pickart 2015)
- Hair follicle stimulation in topical scalp applications (research and cosmetic use)
- Antioxidant activity via superoxide dismutase enzyme support
- Broad gene-expression modulation across DNA repair, extracellular matrix, and inflammatory pathways (Pickart 2018 microarray characterisation)
- Investigational systemic tissue-repair applications for injectable use (more limited controlled evidence)
Mechanism of action
GHK-Cu is unusual among the peptides on Healthy Mango in one specific respect: it is not a synthetic research compound at all. It is a naturally occurring tripeptide — glycyl-L-histidyl-L-lysine — bound to copper(II) as its physiologically active form. Loren Pickart isolated the sequence from human plasma in 1973 and immediately noted its copper-binding behaviour. That fifty-year continuous research history is one editorial anchor for how the compound should be read.
The mechanistic story turns out to be less about the peptide than about the metal it carries. Copper is an essential micronutrient — a cofactor for lysyl oxidase (extracellular matrix cross-linking), superoxide dismutase (antioxidant defense), cytochrome c oxidase (mitochondrial energy production), and dopamine β-hydroxylase (neurotransmitter synthesis). Cells need copper delivered to them, but free copper is cytotoxic. Endogenous copper-transport proteins (ceruloplasmin, ATP7A, ATP7B, the copper chaperones) exist precisely because copper delivery is a solved biological problem. GHK-Cu is one participant in that transport system: the tripeptide chelates copper stably at physiological pH, delivers it into cells, and releases it to intracellular targets.
The consequence of this mechanism is what makes GHK-Cu editorially distinctive. Because copper acts as cofactor for so many enzymes across so many pathways, delivering copper to cells produces downstream gene-expression changes in an enormous number of genes. Pickart and Margolina published genome-wide microarray studies characterising this footprint: at physiological GHK-Cu concentrations, approximately 4200 human genes are significantly modulated, including genes involved in DNA repair, extracellular matrix synthesis, antioxidant defense, angiogenesis, and inflammatory response. This is not a compound with 'a mechanism' in the singular sense. It is a compound with a mechanism (copper delivery) whose downstream consequences are inherently broad.
The clinical evidence structure follows from this. GHK-Cu has been used as a cosmetic ingredient for decades under the INCI name 'Copper Tripeptide-1,' with an established industry safety and efficacy record. The 2022 systematic review by Zhang et al. in Journal of Cosmetic Dermatology consolidated the topical clinical evidence for wound healing, dermal regeneration, and anti-aging applications. That is the strongest human evidence base for any peptide in Healthy Mango's tissue-repair category. Injectable and systemic GHK-Cu use has less controlled human evidence — but the topical/cosmetic base is genuinely more substantial than what supports BPC-157 or TB-500 in their popular use cases.
- Endogenous — isolated from human plasma by Pickart in 1973 and continuously researched since
- Modulates the largest number of human genes (~4200) characterised for any small research peptide; the breadth comes from copper's role as cofactor across many enzyme families
- Genuinely FDA-approved as a topical cosmetic ingredient (INCI Copper Tripeptide-1); not approved as a systemic therapeutic drug
Human research
The GHK-Cu research base is anchored in a research program that has continued essentially without interruption for fifty years — Loren Pickart isolated the tripeptide from human plasma in 1973 and remains associated with the peptide's mechanistic characterisation as recently as 2018. Pickart 2015 in BioMed Research International is the widely cited consolidating review that lays out the copper-delivery mechanism and its downstream tissue-repair consequences. Pickart 2018 in International Journal of Molecular Sciences extends the mechanistic case with the genome-wide microarray characterisation — the source of the frequently cited '~4200 human genes' modulation footprint.
The dermatology clinical literature has developed largely in parallel through the cosmetic industry. Zhang 2022 in Journal of Cosmetic Dermatology is a recent systematic review of GHK-Cu clinical evidence in wound healing and dermal repair contexts — the strongest single systematic review supporting the topical use case. That evidence structure is fundamentally different from the tissue-repair literature for BPC-157 or TB-500, both of which lack systematic-review support at this level.
Evidence level of B (moderate) reflects this structure: strong mechanistic characterisation across 50 years of research, real dermatology-clinical-evidence base for topical use, more limited controlled evidence for the injectable / systemic route sometimes marketed. The topical use case is the one with the strongest support; extrapolating from it to injectable applications requires appropriate epistemic care.
Pickart & Thaler Nature 1973
The foundational paper. Isolation of the glycyl-histidyl-lysine tripeptide from human plasma and characterisation of its copper-binding behaviour. Establishes GHK-Cu as an endogenous copper-binding peptide rather than a synthetic research compound.
Pickart BioMed Res Int 2015
Consolidating review of GHK-Cu mechanism and clinical evidence for skin regeneration. Lays out the copper-delivery-to-tissue-repair mechanism, documents topical efficacy at cosmetic concentrations, and organises the research base by tissue system.
Pickart & Margolina IJMS 2018
Genome-wide microarray characterisation of GHK-Cu gene expression modulation. Documents significant modulation of approximately 4200 human genes at physiological concentrations, including genes in DNA repair, extracellular matrix synthesis, antioxidant defense, and inflammation. The source of the frequently cited genome-wide footprint.
Zhang J Cosmet Dermatol 2022
Systematic review of GHK-Cu clinical evidence for cutaneous applications: wound healing, dermal regeneration, and anti-aging. The strongest single evidence-synthesis document supporting the topical use case. Notably absent from most other tissue-repair peptides in this space.
GHK-Cu occupies an unusual regulatory position: it is simultaneously an approved cosmetic ingredient across most jurisdictions AND an unapproved systemic therapeutic drug. The topical/cosmetic side has an extensive regulatory record. GHK-Cu appears in the International Nomenclature of Cosmetic Ingredients (INCI) database under the name 'Copper Tripeptide-1,' has been evaluated by cosmetic-industry safety panels, and is a widely used ingredient in mainstream skincare.
The systemic injectable side has no such regulatory record. There is no FDA-approved GHK-Cu pharmaceutical for any injectable indication. Access to injectable material is via compounding pharmacies (where legally permitted) or research-supply channels. This split matters: someone extrapolating from 'GHK-Cu is a widely used cosmetic ingredient' to 'GHK-Cu injection is regulatory-supported' is making the wrong inference.
The historical development also includes an intermediate step worth noting: Prezatide copper acetate (essentially GHK-Cu) was investigated for wound-healing indications in the 1990s and reached limited pharmaceutical development, though not FDA approval as a wound-healing therapeutic. That development history is part of the compound's identifiable regulatory record.
Safety considerations
GHK-Cu has an established topical cosmetic safety record. Injectable-use safety data is more limited.
- Local skin irritation from topical formulations — Uncommon; characterised in cosmetic-industry safety literature
- Injection-site reactions with subcutaneous use
- Rare copper hypersensitivity
- No systemic toxicity signals from topical cosmetic use — At approved cosmetic concentrations, no systemic safety concerns identified
- Injectable-use long-term safety is not comprehensively characterised in controlled human trials
The contraindications below reflect both the compound's copper-delivery mechanism and the general research-peptide safety class.
- Wilson disease and other copper-metabolism disorders — direct mechanistic contraindication because these conditions involve pathological copper accumulation
- Known copper hypersensitivity
- Concurrent copper-chelation therapy (e.g., D-penicillamine for Wilson disease) — direct mechanistic contradiction
- Pregnancy and breastfeeding for injectable use — no controlled human safety data
- Active malignancy — precautionary consideration given gene-expression modulation breadth
Monitoring
- Local skin response for topical use
- Injection-site reactions for research-context injectable use
- Systemic copper status in individuals with copper-metabolism concerns (relevant for oral or injectable, not for topical cosmetic use)
Frequently asked questions
Is GHK-Cu FDA-approved?
Yes and no — this is where careful framing matters. GHK-Cu is FDA-recognised and legal as a topical cosmetic ingredient. It appears in the INCI cosmetic-ingredient database under the name 'Copper Tripeptide-1' and is widely used in approved skincare products. GHK-Cu is NOT FDA-approved as a systemic therapeutic drug — there is no approved injectable pharmaceutical for any indication. Someone extrapolating from 'cosmetic approval' to 'systemic pharmaceutical approval' is making the wrong inference.
Why does GHK-Cu modulate thousands of genes when other peptides don't?
Because the modulation is downstream of a single upstream event: copper delivery to cells. Copper is a cofactor for many enzymes — lysyl oxidase (matrix cross-linking), superoxide dismutase (antioxidant), cytochrome c oxidase (mitochondrial), dopamine β-hydroxylase (neurotransmitter synthesis), and many others. Any cellular process that has an enzyme with a copper cofactor is potentially affected. Downstream gene expression follows the enzyme activity changes. GHK-Cu doesn't 'target' 4200 genes — it delivers a micronutrient whose absence or presence affects many enzyme systems, and gene expression responds to those systems.
Is topical GHK-Cu the same as injectable GHK-Cu?
The molecule is the same but the evidence bases, the regulatory frameworks, and the appropriate use cases are different. Topical use has decades of cosmetic-industry evidence, established regulatory approval as a cosmetic ingredient, and a systematic review (Zhang 2022) supporting dermatology applications. Injectable use has more limited controlled evidence, no regulatory approval, and access only through compounding channels. Someone asking 'does GHK-Cu work' needs to specify which use case they mean — the answers are meaningfully different.
How is GHK-Cu different from BPC-157 or TB-500 as a tissue-repair peptide?
Fundamentally. GHK-Cu is endogenous — your body already produces and uses it. BPC-157 and TB-500 are synthetic research peptides. GHK-Cu has fifty years of continuous research history and a real clinical evidence base for its topical use case. BPC-157 and TB-500 have popular reputations that exceed their controlled human evidence. GHK-Cu's mechanism (copper delivery) is well-established biochemistry — copper transport is a solved biological problem. BPC-157 and TB-500 mechanisms remain more speculative. If the question is 'which tissue-repair peptide has the strongest evidence,' GHK-Cu is straightforwardly the answer — at least for its topical use case.
Are there safety concerns with regular use?
For topical cosmetic use at approved concentrations, no — GHK-Cu has an established cosmetic-industry safety record and cosmetic dermatology tolerability is generally excellent. For injectable use, safety data is more limited. The main mechanistic contraindication for any route is Wilson disease or other copper-metabolism disorders, because the mechanism specifically involves delivering copper to cells. Individuals with copper-related metabolic conditions should not use GHK-Cu.
References
- [1]
A tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver — Pickart L, Thaler MM, Nature New Biology (1973)
- [2]
GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration — Pickart L, Vasquez-Soltero JM, Margolina A, BioMed Research International (2015)
- [3]
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — Pickart L, Margolina A, International Journal of Molecular Sciences (2018)
- [4]
Cutaneous applications of copper peptide (GHK-Cu) — a systematic review of clinical and preclinical evidence — Zhang Q, Yang C, Wang Y, et al., Journal of Cosmetic Dermatology (2022)
- [5]
Peptides & Compounds — The No-Jargon Guide (v5) — Healthy Mango Editorial, Healthy Mango practitioner reference (2026)
Laboratory Reference Notice
This section summarizes procedures and study parameters reported in published scientific literature and laboratory protocols. It is provided for educational and research reference only and must not be interpreted as medical advice, clinical guidance, or instructions for personal use.
Editorial review pending
This page has not yet undergone external editorial review. Content is drawn from published sources and may be updated as review completes.